RESUMO
OBJECTIVE: Acute pancreatitis can cause local or systemic complications and has high morbidity and mortality rates. In the early stages of pancreatitis, a decrease in the barrier function of the intestines and an increase in bacterial translocation are observed. Zonulin is a marker used to evaluate the integrity of the intestinal mucosal barrier. We aimed to investigate whether measuring serum zonulin levels would contribute to the early prediction of complications and severity in acute pancreatitis. MATERIALS AND METHODS: Our study was an observational, prospective study and included 58 patients with acute pancreatitis and 21 healthy controls. Causes of pancreatitis and serum zonulin levels of the patients at the time they were diagnosed with pancreatitis were recorded. The patients were evaluated in terms of pancreatitis severity, organ dysfunction, complications, sepsis, morbidity, length of hospital stay, and mortality Results: Zonulin levels were higher in the control group and lowest in the severe pancreatitis group. No significant difference was observed in zonulin levels according to disease severity. There was no significant difference between zonulin levels in patients who developed organ dysfunction or sepsis. In patients with acute pancreatitis complications, zonulin levels were found to be significantly lower with a mean of 8.6 ng/mL (P < .02). CONCLUSION: Zonulin levels are not a guide in the diagnosis of acute pancreatitis, in determining its severity, and in the development of sepsis and organ dysfunction. The zonulin level at the time of diagnosis may be helpful in predicting complicated acute pancreatitis. Zonulin levels are not effective in demonstrating necrosis or infected necrosis.
RESUMO
The gamma-glutamyl transferase to platelet ratio (GPR) has been reported to be as effective as the aspartate transaminase to platelet ratio index (APRI) and fibrosis index based on the 4 factors (FIB-4) in showing the fibrosis stage in patients with chronic hepatitis B. It has been demonstrated that APRI and FIB-4 are successful in the assessment of fibrosis in primary biliary cholangitis (PBC). We investigated the effectiveness of GPR in predicting advanced fibrosis and cirrhosis in patients with biopsy-proven untreated PBC. A total of 35 patients with biopsy-proven PBC were included in this study. The biopsy fibrosis stages of all patients at diagnosis were compared using the APRI, FIB-4, and GPR values. The diagnostic accuracy of GPR for detecting advanced fibrosis and cirrhosis was also investigated. The area under the receiver operating characteristic curve (AUROC) of GPR was 0.84, the cutoff point was 4.81, the sensitivity was 0.41, and the specificity was 0.96 for detecting advanced fibrosis. Our study showed that GPR was more sensitive than APRI and FIB-4 in detecting advanced fibrosis in patients with PBC. GPR could be used as an effective noninvasive marker in PBC to show advanced fibrosis at the time of diagnosis.
Assuntos
Hepatite B Crônica , Cirrose Hepática Biliar , Aspartato Aminotransferases , Biópsia , Hepatite B Crônica/patologia , Humanos , Cirrose Hepática/diagnóstico , Cirrose Hepática/patologia , Cirrose Hepática Biliar/complicações , Cirrose Hepática Biliar/diagnóstico , Contagem de Plaquetas , Curva ROC , Estudos Retrospectivos , Índice de Gravidade de Doença , gama-GlutamiltransferaseRESUMO
BACKGROUND: Endotrophin, a type VI collagen cleavage product, has fibrosis, and insulin resistance effects. Type VI collagen also plays a role in cardiac fibrosis. In this study, we aimed to investigate the role of endotrophin in the pathogenesis of cardiac fibrosis by determining its levels in patients with heart failure with reduced and mid-range ejection fraction (EF). We also aimed to determine the possible association between endotrophin and treatment that prevents ventricular fibrosis. METHODS: Sixty patients with heart failure with reduced and mid-range EF and 27 volunteers with no cardiac failure were included in this study. In both groups, biochemical tests, EF, and endotrophin levels were measured. ELISA was performed for the determination of endotrophin levels. RESULTS: When compared with the control group, there was no significant difference for endotrophin levels in the patient group (pâ¯=â¯.35). Participants in the study were divided into two groups according to their EFs, 40% and less, and 40-49%. They were classified according to their use of renin-angiotensin-aldosterone system (RAAS) blocking drugs. Endotrophin levels were significantly lower in patients with mid-range EFs between 40 and 49% (pâ¯=â¯.03) using RAAS blockers. CONCLUSION: This study is the first to evaluate the relationship between endotrophin and heart failure. Endotrophin levels were found to be low in patients with heart failure with mid-range EF who were using RAAS blockers. This suggests that RAAS blockers may influence endotrophin levels and thus could have a role in the prevention of remodelling.
Assuntos
Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Colágeno Tipo VI/sangue , Insuficiência Cardíaca/tratamento farmacológico , Fragmentos de Peptídeos/sangue , Volume Sistólico , Idoso , Estudos de Casos e Controles , Feminino , Insuficiência Cardíaca/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Sistema Renina-Angiotensina/efeitos dos fármacosRESUMO
OBJECTIVES: Adropin is a novel marker of metabolic syndrome and insulin resistance. The aim of this study was to explore the association of serum adropin levels with hepatosteatosis among adult patients. MATERIALS AND METHODS: Serum biochemical parameters including liver and renal function tests, insulin levels, and serum adropin levels were compared between adult patients with nonalcoholic fatty liver disease (NAFLD) and healthy control cases. RESULTS: A total of 51 patients with a mean age of 37.9 ± 9.96 years diagnosed with grade 2-3 hepatosteatosis and 30 healthy control cases with a mean age of 34.8 ± 9.5 years were included in the study. Serum adropin levels in the NAFLD group were statistically significantly lower than in the control cases (588.4 ± 261.0 vs. 894.2 ± 301.2, respectively; p < 0.001). The study participants were further subdivided into 2 groups as patients with (n = 35) or without (n = 46) insulin resistance using the serum homeostatic model of assessment-insulin resistance (HOMA-IR). Serum adropin levels were statistically significantly lower in patients with insulin resistance (p < 0.01). There was a negative correlation between adropin levels and serum insulin, HOMA-IR, urea, gamma-glutamyl transferase, total cholesterol, and triglyceride levels. CONCLUSION: We observed a decrease in serum adropin levels among adult patients with NAFLD. We also found lower levels of serum adropin in patients with insulin resistance, supporting previous data in the literature. Studies investigating the association of adropin levels with other inflammatory parameters are warranted to define its exact role in the pathogenesis of hepatosteatosis.
Assuntos
Resistência à Insulina , Peptídeos e Proteínas de Sinalização Intercelular/sangue , Hepatopatia Gordurosa não Alcoólica/sangue , Adulto , Estudos de Casos e Controles , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , TurquiaRESUMO
OBJECTIVE: The aim of this study was to determine how often the recommendations of the Turkish Hypertension Consensus Report are followed, and to draw attention to the report. METHODS: The demographic information of 1000 patients diagnosed with hypertension and the details of the antihypertensive medications prescribed at the outpatient service of a tertiary care hospital were recorded, and the data were compared with the recommendations of the report. RESULTS: The mean age of the patients was 62±11 years. In all, 623 (62.3%) of the 1000 patients were women, and 377 (37.7%) were men. A combination of an angiotensin II receptor blocker (ARB) and a diuretic was the most frequently observed prescription. A diuretic was the most used antihypertensive drug (58.7%), followed by an ARB (48.8%). However, as a monotherapy, a calcium channel blocker (CCB) was the most commonly used antihypertensive drug (19.2%). The most frequently used antihypertensive drug group in older patients was diuretics (63.6%), as proposed in the report. Beta blockers (49.1%) were used more often than expected. For the diabetic group also, a diuretic (60.7%) was the most frequently used antihypertensive drug, followed by an ARB (51.1%) and a CCB (45.2%). Angiotensin-converting enzyme (ACE) inhibitors (34.6%) were the fifth most preferred antihypertensive drug class. However, when ACE inhibitors and ARBs were considered as a single group, known as renin-angiotensin system (RAS) blockers, these RAS blockers were the most prescribed antihypertensive drug class, followed by diuretics. In the group of patients with coronary artery disease, treatment was found to be generally consistent with the report, but the use of diuretics was greater than expected. Lastly, 124 of 160 patients who had chronic kidney disease were given RAS blocker therapy, which was in line with the consensus report recommendations. CONCLUSION: Antihypertensive therapies were individualized, as suggested by the consensus report. However, there are proposals still to be considered in special patient groups.